Le Lézard
Classified in: Health, Science and technology

Red Spot Interactive and NextGen Healthcare Build Partnership to Strengthen Patient Acquisition and Provider Retention


JUPITER, Fla., Sept. 17, 2019 /PRNewswire-PRWeb/ -- Red Spot Interactive (RSI), a marketing and patient acquisition company, is proud to establish a new partnership with NextGen Healthcare Inc., a leading healthcare solutions provider for ambulatory and specialty practices. This adds to RSI's growing list of partners, which include Nextech, DrChrono, Symplast and Azalea, with additional partnerships to announce in the near future. The partnership will equip NextGen Healthcare consumers with marketing and patient scheduling performance solutions, patient retention solutions, and appointment request software.

"NextGen is a leader in providing software for healthcare solutions for ambulatory and specialty practices," said Jason Tuschman, CEO and Founder of Red Spot Interactive. "We appreciate their drive to provide such solutions and look forward to seeing our mutual practices grow stronger and excel with respect to ROI-driven patient acquisition and management."

By merging with Red Spot Interactive and utilizing the company's integrated tools and technology, NextGen Healthcare clients will have the opportunity to:

Through these advanced tools, NexGen consumers will have access to invaluable information that will allow them to develop a thorough understanding of their marketing ROI and patient scheduling challenges, as well as their consultation and service performance from a consumer perspective.

 

SOURCE Red Spot Interactive


These press releases may also interest you

at 20:35
La Jolla Institute for Immunology and RevolKa started a Research Collaboration
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

at 19:05
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIOŽ (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIOŽ (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...

at 18:42
Media Advisory - Minister Saks in Winnipeg to highlight Budget 2024: Fairness for Every Generation investments to boost research funding in Canada
The Honourable Ya'ara Saks, Minister of Mental Health and Addictions and Associate Minister of Health, will host an event at the University of Manitoba to highlight the federal budget's investments to boost funding for research in Canada. A media...

at 18:18
Targeting A Solution Panel Aims to Find Solutions for the Veteran Suicide Crisis with National Thought Leaders Tulsi Gabbard, Tim Kennedy, and Dan Hollaway
Targeting a Solution is an insightful and impactful fireside discussion dedicated to ending Veteran suicide that will have its next iteration on April 20th, 2024, in Kannapolis, NC hosted by The Independence Fund. The panel will feature four-term...

at 18:15
Equality Health Foundation Expands Reach to Virginia and Louisiana
Equality Health Foundation, the philanthropic partner of Equality Health LLC and an organization dedicated to advancing health equity and improving well-being access for underserved communities, proudly announces its expansion into Virginia and...

at 18:01
Aflac Incorporated Revises Time of First Quarter Webcast Teleconference to 7:00 a.m. (ET) on Thursday, May 2, 2024
Aflac Incorporated announced today that it has revised the time of its first quarter webcast teleconference call on Thursday, May 2, 2024 to 7:00 a.m. (ET), which is one hour earlier than the originally scheduled 8:00 a.m. start time, to avoid...

More news about Health...


News published on and distributed by: